Upbeat Nystagmus in Organophosphate Poisoning
Yes, upbeat nystagmus has been described with organophosphate poisoning, though it is a rare CNS manifestation that resolves with appropriate atropine treatment.
Evidence for Upbeat Nystagmus
A case report documented primary position upbeat nystagmus (vertical jerk nystagmus with fast upward phase present in primary position) in a 21-month-old child who ingested an organophosphate pesticide 1. The diagnosis was confirmed by markedly depressed RBC and plasma cholinesterase levels, and the nystagmus rapidly resolved following intravenous atropine administration 1.
This represents a rare CNS manifestation of organophosphate toxicity, distinct from the more commonly recognized CNS effects.
Standard CNS Manifestations of Organophosphate Poisoning
The typical CNS effects of organophosphate poisoning include 2:
- Altered mental status
- Central apnea
- Seizures
These occur alongside:
- Muscarinic effects: bradycardia, bronchospasm, bronchorrhea, miosis, hypersalivation, lacrimation, urination, diarrhea, vomiting, diaphoresis
- Nicotinic effects: tachycardia, mydriasis, fasciculations progressing to neuromuscular blockade and paralysis
Clinical Implications
When encountering upbeat nystagmus in a patient with suspected organophosphate exposure:
- Confirm the diagnosis with cholinesterase levels (RBC and plasma)
- Initiate immediate atropine therapy - this addresses both the nystagmus and life-threatening manifestations 2
- Expect resolution of the nystagmus with appropriate anticholinergic treatment 1
Treatment Priority
The presence of upbeat nystagmus should not alter standard management protocols. Immediate atropine administration remains the cornerstone of treatment for severe organophosphate poisoning 2. The initial dose should be doubled every 5 minutes until full atropinization is achieved (clear chest on auscultation, heart rate >80/min, systolic blood pressure >80 mm Hg) 2.
Important caveat: While upbeat nystagmus has been documented, it is an uncommon finding. Its presence should prompt consideration of organophosphate toxicity in the appropriate clinical context, but its absence does not exclude the diagnosis.